ERBB2 and neoplasm: Although the effective HER2-targeted treatments have radically reduced the risk of recurrence and improved the survival of HER2+ BC patients, a significant proportion of patients ultimately develop resistance to these therapies, largely because of tumor heterogeneity 5-7.